Accumulating preclinical evidence indicates that PDE inhibitors promote learning and memory, and inhibition of PDE10A has been suggested as a promising therapeutic strategy for psychiatric and neurodegenerative diseases, based on its efficacy in animal models of schizophrenia and AD [55]. Here, PDE10A is linked to schizophrenia.